TCGA-86-8278-01A-11R-2287-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- INTERFERON_GAMMA_RESPONSE+0.210
- PROTEIN_SECRETION+0.210
- ANGIOGENESIS+0.160
- NOTCH_SIGNALING+0.160
- HEME_METABOLISM+0.150
- UNFOLDED_PROTEIN_RESPONSE+0.130
- UV_RESPONSE_DN+0.110
Top 10 suppressed
- E2F_TARGETS-0.530
- MYC_TARGETS_V1-0.470
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V2-0.440
- OXIDATIVE_PHOSPHORYLATION-0.440
- SPERMATOGENESIS-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- MTORC1_SIGNALING-0.170
- KRAS_SIGNALING_DN-0.160
- PANCREAS_BETA_CELLS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A73W-01A-22R-A352-07 | — | B | 0.820 |
| 2 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.797 |
| 3 | TCGA-B6-A0RP-01A-21R-A084-07 | — | B | 0.793 |
| 4 | TCGA-44-2665-01A-01R-0946-07 | — | cohortA1 | 0.790 |
| 5 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.779 |
| 6 | 2b1fa47d-360a-4b4a-aa11-23bdb025b559 | — | — | 0.774 |
| 7 | TCGA-91-6830-01A-11R-1949-07 | — | cohortMD2 | 0.769 |
| 8 | TCGA-XF-A9SK-01A-11R-A42T-07 | — | — | 0.768 |
| 9 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.766 |
| 10 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |